CSA fine for J&J
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson will pay $511,000 in fines because imports of pseudoephedrine-containingBenedryl-D to a manufacturing facility in Lititz, Pa., were not reported as required by the Controlled Substances Act, according to an Aug. 5 settlement with the Department of Justice. The U.S. Attorney's Office for the Eastern District of Pennsylvania and J&J subsidiary McNeil-PPC explain the unreported imports of the OTC nasal decongestant tablets occurred during 2001 to 2005, when Pfizer's Warner-Lambert business owned the facility. J&J acquired the facility in 2006 when it bought Pfizer Consumer Healthcare (1"The Tan Sheet" Dec. 18, 2006, p. 9). DOJ says the CSA requires companies to file reports with the Drug Enforcement Agency within 15 days of importing products containing pseudophedrine and other specified chemicals that can be used in manufacturing controlled substances...